Drug intelligence / Profile preview

CG209

Development stage: Preclinical
Lead developer: ConverGene
Modality: Small Molecules

Overview

CG209 is a small molecule dopamine D2 receptor (DRD2) inhibitor being developed by ConverGene for the treatment of neurological and psychiatric disorders. Currently in the discovery and lead optimization stages of preclinical development, CG209 is designed to modulate dopaminergic signaling pathways that are central to various central nervous system (CNS) pathologies. Unlike other candidates in ConverGene's pipeline that utilize dual-targeting mechanisms (such as dual BET/DRD2 inhibitors for oncology), CG209 is specifically focused on DRD2 inhibition for CNS-related indications.

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on CG209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG209.

Explore the full profile